Core Viewpoint - The company, New Industry Biomedical Engineering Co., Ltd., has experienced a decline in stock price and a mixed financial performance, with a slight increase in revenue but a significant decrease in net profit [1][2]. Group 1: Stock Performance - On January 20, the stock price of New Industry fell by 2.05% to 56.76 CNY per share, with a trading volume of 112 million CNY and a turnover rate of 0.29%, resulting in a total market capitalization of 44.597 billion CNY [1]. - Year-to-date, the stock price has increased by 0.91%, but it has decreased by 4.96% over the last five trading days, 3.80% over the last 20 days, and 8.32% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 3.428 billion CNY, representing a year-on-year growth of 0.39%, while the net profit attributable to shareholders was 1.205 billion CNY, reflecting a year-on-year decrease of 12.92% [2]. - Cumulatively, since its A-share listing, the company has distributed a total of 3.86 billion CNY in dividends, with 2.357 billion CNY distributed over the last three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 15.87% to 13,100, with an average of 51,997 circulating shares per shareholder, which is an increase of 18.87% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fourth largest, holding 26.4824 million shares, an increase of 4.2383 million shares from the previous period [3].

Group 1 - New Industry's stock price has dropped 1.27% to 58.96 CNY per share, with a trading volume of 425 million CNY and a turnover rate of 1.06%, resulting in a total market capitalization of 46.326 billion CNY [1] - The stock has experienced a continuous decline over three days, with a cumulative drop of 6.14% [1] - New Industry Biomedical Engineering Co., Ltd. specializes in the research, development, production, and sales of fully automated chemiluminescence immunoassay instruments and related reagents, with revenue composition of 69.62% from reagents, 30.21% from instruments, and 0.16% from other sources [1] Group 2 - Huazhang Fund has one fund heavily invested in New Industry, specifically the Huazhang CSI Medical Device Index Fund A (021469), which increased its holdings by 8,900 shares to a total of 15,300 shares, representing 3.33% of the fund's net value, making it the fifth largest holding [2] - The fund has incurred a floating loss of approximately 11,600 CNY today and a total floating loss of 59,100 CNY during the three-day decline [2] - The Huazhang CSI Medical Device Index Fund A (021469) was established on November 5, 2024, with a latest scale of 15.8869 million CNY, and has achieved a year-to-date return of 11.11% and a one-year return of 18.53% [2] Group 3 - The fund manager of Huazhang CSI Medical Device Index Fund A is Su Qingyun, who has a tenure of 9 years and 29 days, managing total assets of 4.628 billion CNY, with the best fund return during the tenure being 127.62% and the worst being -62.44% [3]

Core Viewpoint - The stock price of New Industry has shown a positive trend, with a year-to-date increase of 10.83%, indicating strong market interest and potential growth in the biomedical sector [2]. Group 1: Stock Performance - As of January 9, New Industry's stock price increased by 2.01%, reaching 62.34 CNY per share, with a trading volume of 66.98 million CNY and a turnover rate of 0.16% [1]. - The stock has experienced a 10.83% increase in price this year, with a 10.83% rise over the last five trading days and a 7.30% increase over the last 20 days, while it has slightly decreased by 0.45% over the last 60 days [2]. Group 2: Company Overview - New Industry, established on December 15, 1995, and listed on May 12, 2020, is based in Shenzhen, Guangdong Province, specializing in the research, development, production, and sales of fully automated chemiluminescence immunoassay instruments and related reagents [2]. - The company's revenue composition is as follows: reagents account for 69.62%, instruments for 30.21%, and other sources for 0.16% [2]. Group 3: Financial Performance - For the period from January to September 2025, New Industry reported a revenue of 3.428 billion CNY, reflecting a year-on-year growth of 0.39%, while the net profit attributable to shareholders decreased by 12.92% to 1.205 billion CNY [2]. - Since its A-share listing, New Industry has distributed a total of 3.86 billion CNY in dividends, with 2.357 billion CNY distributed over the past three years [3]. Group 4: Shareholder Information - As of September 30, 2025, the number of shareholders for New Industry was 13,100, a decrease of 15.87% from the previous period, with an average of 51,997 circulating shares per shareholder, an increase of 18.87% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 26.4824 million shares, an increase of 4.2383 million shares from the previous period, while other notable shareholders include Huabao Zhongzheng Medical ETF and Yifangda Blue Chip Selected Mixed Fund [3].

Core Viewpoint - The company, New Industry Biomedical Engineering Co., Ltd., has experienced a decline in stock price and financial performance, with a notable drop in net profit despite a slight increase in revenue [1][2]. Financial Performance - As of September 30, 2025, New Industry reported a revenue of 3.428 billion yuan, representing a year-on-year growth of 0.39% [2]. - The net profit attributable to shareholders was 1.205 billion yuan, showing a decrease of 12.92% compared to the previous period [2]. - The company's stock price has decreased by 17.04% year-to-date, with a 2.53% drop over the last five trading days and a 14.67% decline over the past 60 days [1]. Shareholder Information - The number of shareholders as of September 30, 2025, was 13,100, a decrease of 15.87% from the previous period [2]. - The average number of circulating shares per shareholder increased by 18.87% to 51,997 shares [2]. Dividend Distribution - Since its A-share listing, New Industry has distributed a total of 3.86 billion yuan in dividends, with 2.357 billion yuan distributed over the last three years [3]. Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited was the fourth-largest circulating shareholder, holding 26.4824 million shares, an increase of 4.2383 million shares from the previous period [3]. - The top ten circulating shareholders include various ETFs, with some increasing and others decreasing their holdings [3].

Core Insights - New Industry Company reported a revenue of 3.428 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 0.39%, while the net profit attributable to shareholders decreased by 12.92% to 1.205 billion yuan [1] - The gross margin for the first three quarters of 2025 was 68.73%, down by 3.62 percentage points compared to the same period last year, and the net profit margin was 35.15%, a decrease of 5.37 percentage points year-on-year [1] - The company incurred operating expenses of 1.012 billion yuan during the first three quarters, an increase of 97.483 million yuan year-on-year, with an expense ratio of 29.54%, up by 2.74 percentage points from the previous year [1] Financial Performance - The basic earnings per share for the first three quarters of 2025 was 1.53 yuan [1] - The company’s operating income for the first half of 2025 was 2.185 billion yuan, a decline of 1.18% year-on-year, with a net profit of 771 million yuan, down 14.62% [7] Shareholder Activity - Shareholder Rao Jie completed a share reduction plan, selling a total of 1.5 million shares, which accounted for 0.1909% of the company's total share capital [6][7] - The total amount from the share reduction was approximately 86.3685 million yuan, calculated based on the average prices of the shares sold [7] Management Information - Rao Wei, the chairman of New Industry, received a salary of 4.471 million yuan in 2024, a slight decrease from 4.592 million yuan in the previous year [3] - Rao Jie, who is the daughter of Rao Wei, received a salary of 1.2 million yuan in the same year [3]

Core Viewpoint - New Industry's stock price has shown fluctuations, with a recent increase of 2.00% and a total market capitalization of 48.887 billion yuan, despite a year-to-date decline of 10.54% [1] Financial Performance - For the period from January to September 2025, New Industry achieved a revenue of 3.428 billion yuan, reflecting a year-on-year growth of 0.39%, while the net profit attributable to shareholders decreased by 12.92% to 1.205 billion yuan [2] - Cumulative cash dividends since the A-share listing amount to 3.860 billion yuan, with 2.357 billion yuan distributed over the past three years [3] Shareholder Structure - As of September 30, 2025, the number of shareholders decreased by 15.87% to 13,100, with an average of 51,997 circulating shares per person, an increase of 18.87% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 4.2383 million shares, and new shareholder E Fund Blue Chip Select Mixed Fund, holding 1.10001 million shares [3] Stock Performance - The stock has experienced a 1.73% increase over the last five trading days, an 8.93% decline over the last 20 days, and a 14.69% increase over the last 60 days [1] Business Overview - New Industry, established on December 15, 1995, specializes in the research, development, production, and sales of fully automated chemiluminescence immunoassay instruments and related reagents, with reagent sales contributing 69.62% to revenue [1] - The company operates within the pharmaceutical and biomedical industry, specifically in the medical device and in vitro diagnostics sectors [1]

Core Viewpoint - The company, established in 1995 and listed in 2020, is a leading player in the domestic chemiluminescence immunodiagnostic field, focusing on the development, production, and sales of fully automated chemiluminescence immunoassay instruments and related reagents [1] Group 1: Business Performance - In Q3 2025, the company's revenue reached 3.428 billion yuan, ranking first among 39 companies in the industry, with the second-ranked company, Antu Biology, at 3.127 billion yuan [2] - The net profit for Q3 2025 was 1.205 billion yuan, placing the company second in the industry, with the top company, Jiuan Medical, at 1.588 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, the company's debt-to-asset ratio was 8.69%, an increase from 8.12% year-on-year, but still below the industry average of 18.29% [3] - The gross profit margin for Q3 2025 was 68.73%, down from 72.34% year-on-year, yet higher than the industry average of 56.20% [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 15.87% to 13,100, while the average number of circulating A-shares held per shareholder increased by 18.87% to 52,000 [5] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited ranked fourth with 26.4824 million shares, an increase of 4.2383 million shares from the previous period [5] Group 4: Management Compensation - The chairman, Rao Wei, received a salary of 4.4712 million yuan in 2024, a decrease of 120,800 yuan from 2023 [4] Group 5: Market Outlook - According to Huazhang Securities, the company faced overall performance pressure in the first three quarters of 2025, but Q3 showed a significant recovery trend, with overseas main business revenue growing by 21.07% year-on-year [6] - The company is expected to achieve revenues of 4.567 billion, 5.211 billion, and 5.873 billion yuan from 2025 to 2027, with net profits of 1.761 billion, 2.001 billion, and 2.397 billion yuan respectively [6]

Core Viewpoint - New Industry's stock price has shown fluctuations with a recent increase of 2.06%, reflecting a total market capitalization of 53.31 billion yuan, while the company faces a decline in revenue and net profit year-on-year [1][2]. Financial Performance - For the first half of 2025, New Industry reported operating revenue of 2.185 billion yuan, a year-on-year decrease of 1.18%, and a net profit attributable to shareholders of 771 million yuan, down 14.62% compared to the previous year [2]. - The company's stock price has decreased by 2.44% year-to-date, with a 1.05% decline over the last five trading days, but has increased by 15.00% over the last 20 days and 23.07% over the last 60 days [1]. Shareholder Information - As of June 30, 2025, the number of shareholders for New Industry decreased by 19.09% to 15,600, while the average number of circulating shares per person increased by 23.59% to 43,743 shares [2]. - The company has distributed a total of 3.860 billion yuan in dividends since its A-share listing, with 2.357 billion yuan distributed over the last three years [3]. Institutional Holdings - Among the top ten circulating shareholders as of June 30, 2025, Hong Kong Central Clearing Limited is the fifth largest with 22.2441 million shares, an increase of 11.0924 million shares from the previous period [3]. - Other notable institutional shareholders include Huabao Zhongzheng Medical ETF and Yifangda Growth Enterprise Board ETF, which have also increased their holdings [3].

Core Viewpoint - The company, Shenzhen New Industry Biomedical Engineering Co., Ltd., has shown a mixed performance in stock price and financial results, with a recent increase in stock price but a decline in revenue and net profit year-on-year [1][2]. Financial Performance - As of June 30, 2025, the company reported a revenue of 2.185 billion yuan, a year-on-year decrease of 1.18% [2]. - The net profit attributable to shareholders was 771 million yuan, reflecting a year-on-year decrease of 14.62% [2]. - The company has distributed a total of 3.860 billion yuan in dividends since its A-share listing, with 2.357 billion yuan distributed in the last three years [3]. Stock Market Activity - On September 11, the stock price increased by 2.05%, reaching 69.19 yuan per share, with a trading volume of 120 million yuan and a turnover rate of 0.26% [1]. - The total market capitalization of the company is 54.364 billion yuan [1]. - Year-to-date, the stock price has decreased by 0.52%, but it has increased by 6.73% over the last five trading days and by 20.75% over the last 20 days [1]. Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 19.09% to 15,600, while the average number of tradable shares per person increased by 23.59% to 43,743 shares [2]. - The top ten circulating shareholders include significant institutional investors, with Hong Kong Central Clearing Limited being the fifth largest shareholder, increasing its holdings by 11.0924 million shares [3].